'Since the launch of its DNA testing service in 2007, genomics giant 23andMe has convinced more than 5 million people to fill a plastic tube with half a teaspoon of saliva. In return for all that spit (and some cash too), customers get insights into their biological inheritance, from the superficial—do you have dry earwax or wet?—to mutations associated with disease. What 23andMe gets is an ever-expanding supply of valuable behavioral, health, and genetic information from the 80 percent of its customers who consent to having their data used for research.
So last week’s announcement that one of the world’s biggest drugmakers, GlaxoSmithKline, is gaining exclusive rights to mine 23andMe’s customer data for drug targets should come as no surprise. (Neither should GSK’s $300 million investment in the company). 23andMe has been sharing insights gleaned from consented customer data with GSK and at least six other pharmaceutical and biotechnology firms for the past three and a half years. And offering access to customer information in the service of science has been 23andMe’s business plan all along, as WIRED noted when it first began covering the company more than a decade ago.
But some customers were still surprised and angry, unaware of what they had already signed (and spat) away. GSK will receive the same kind of data pharma partners have generally received—summary level statistics that 23andMe scientists gather from analyses on de-identified, aggregate customer information—though it will have four years of exclusive rights to run analyses to discover new drug targets. Supporting this kind of translational work is why some customers signed up in the first place. But it’s clear the days of blind trust in the optimistic altruism of technology companies are coming to a close.
“I think we’re just operating now in a much more untrusting environment,” says Megan Allyse, a health policy researcher at the Mayo Clinic who studies emerging genetic technologies. “It’s no longer enough for companies to promise to make people healthy through the power of big data.” Between the fall of blood-testing unicorn Theranos and Facebook’s role in the 2016 election attacks, “I think everything from here on out will be subject to much higher levels of public scrutiny,” Allyse says.
23andMe maintains that transparency is a core tenet of the company. “I think a really important distinction to make is that 23andMe operates under an independent ethical review board that oversees all of our research,” says Emily Drabant Conley, 23andMe’s vice president of business development, who oversaw the announcement of the GSK deal. “The guidelines we follow are essentially the same as what other research institutions follow.” So they should apply to any of the analyses GSK might want to run on 23andMe data, like a PheWAS, which connects constellations of symptoms and conditions across many people with a single genetic mutation they all share.'
Read more: 23andMe's Pharma Deals Have Been the Plan All Along
Did you like this article?
Thank you for your vote!
IF Truth Be Told About Vaccines! Risk Of SEIZURES After MMR & DTP Vaccinations Exist Per CDC Vaccine Safety Datalink Working Group
10 March 2019
Doctors accuse Britain's first medical cannabis clinic of making unfounded claims over pain relief
4 March 2019
Kills more than just pain: Study proves Tylenol has damaging effects on children’s brains
2 March 2019
ANOTHER cancer-causing toxin found in recalled blood pressure pills, FDA reveals amid global drug recall that has lasted 9 months - exposing millions Americans to carcinogens
From our advertisers
56 minutes ago
UN human rights chief decries US choking of Venezuela as Trump mulls imposing ‘toughest’ sanctions
14 hours ago
Defiant EU chief Tusk sets up dramatic final showdown between May and MPs after insisting Brexit will only be delayed if she can get her deal through Parliament NEXT WEEK
'Renegade' - The Life Story of David Icke (Official Trailer) - 2019 - And where you can see it...
20 February 2019
Australian petition demanding David Icke be allowed into the country passes 15,000 and increasing all the time
From our advertisers